Establishment Labs (NASDAQ:ESTA) Releases Earnings Results, Misses Estimates By $0.05 EPS

Establishment Labs (NASDAQ:ESTA) posted its quarterly earnings data on Thursday. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05), FiscalAI reports. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. During the same period in the prior year, the firm posted ($0.57) EPS. The firm’s revenue for the quarter was up 31.7% on a year-over-year basis.

Here are the key takeaways from Establishment Labs’ conference call:

• Positive Sentiment: Q2 revenue rose 31.7% year over year to $67.5 million, led by U.S. revenue growth of 140.9% to $24.7 million. Management raised full-year revenue guidance to $269 million-$271 million.
• Positive Sentiment: U.S. adoption of Motiva continued to accelerate, surpassing 100,000 implants and 2,000 customer accounts in under 21 months. Increasing utilization within existing accounts and growing patient requests for Motiva are supporting momentum.
• Positive Sentiment: The minimally invasive platform generated $12.1 million in Q2 revenue and is expected to approach 15% of full-year revenue. Preservé training exceeded expectations with more than 300 certified U.S. surgeons, while the company expects to train approximately 500 during 2026.
• Positive Sentiment: Profitability and cash generation improved substantially, with gross margin expanding to 70.6% and adjusted EBITDA turning positive at $3.7 million versus a prior-year loss of $8.5 million. Management expects to become free-cash-flow positive in the second half of 2026 and for fiscal 2027, without needing additional equity raises.
• Negative Sentiment: The third quarter is expected to reflect normal seasonal weakness, with the fourth quarter typically strongest. Middle East distributor demand has fallen because of regional conflict and is expected to remain depressed for the rest of the year, although the region represents less than 5% of revenue.

Establishment Labs Stock Performance

Shares of ESTA traded down $0.30 during mid-day trading on Friday, reaching $78.75. The company had a trading volume of 365,588 shares, compared to its average volume of 552,956. Establishment Labs has a 52-week low of $33.35 and a 52-week high of $97.59. The stock has a market capitalization of $2.32 billion, a P/E ratio of -52.29 and a beta of 1.07. The stock has a 50 day moving average of $86.29 and a two-hundred day moving average of $74.23. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82.

Establishment Labs News Summary

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Management guided to fiscal 2026 revenue of $269 million to $271 million, above the $267.5 million analyst consensus. The company also said minimally invasive procedures now represent approximately 15% of sales, highlighting an expanding growth opportunity. Establishment Labs signals 2026 revenue guidance
• Positive Sentiment: Second-quarter revenue reached $67.54 million, beating expectations of $65.79 million and increasing 31.7% year over year. The loss narrowed to $0.39 per share from $0.57 a year earlier, indicating continued commercial momentum. Establishment Labs Q2 results
• Positive Sentiment: BTIG Research raised its price target from $96 to $103 and maintained a Buy rating. Needham also lifted its target from $86 to $95 with a Buy rating, signaling increased confidence in the company’s growth outlook.
• Neutral Sentiment: The earnings call emphasized the company’s growing minimally invasive business and broader adoption of its products, but investors will likely monitor whether this expansion translates into improved profitability.
• Negative Sentiment: ESTA reported a quarterly loss of $0.39 per share, worse than the expected loss of $0.34. The company remains unprofitable, with analysts expecting a full-year loss, limiting the positive impact of the revenue beat.

Analyst Ratings Changes

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday. TD Cowen raised their price target on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday. Needham & Company LLC upped their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Finally, Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a report on Thursday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Establishment Labs presently has an average rating of “Moderate Buy” and an average target price of $100.25.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in ESTA. ADAR1 Capital Management LLC raised its stake in Establishment Labs by 89.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock valued at $12,493,000 after purchasing an additional 80,734 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Establishment Labs in the fourth quarter valued at about $3,421,000. SummitTX Capital L.P. purchased a new position in shares of Establishment Labs in the fourth quarter worth about $2,519,000. Tudor Investment Corp ET AL acquired a new position in Establishment Labs during the fourth quarter worth about $12,852,000. Finally, Twinbeech Capital LP purchased a new stake in Establishment Labs during the 4th quarter valued at about $214,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.